Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 233,238,903 papers from all fields of science
Search
Sign In
Create Free Account
Eye Drops
Known as:
EYE DROP
, Ophthalmic Drops [Dose Form]
, Drops, Eye
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
EYE DROP,AUTODROP DEVICE
Eye drops brand of Tetrahydrozoline
Broader (1)
Ophthalmic Solution
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Noninvasive delivery of gene targeting probes to live brains for transcription MRI
Christina Liu
,
Zerong You
,
Jiaqiang Ren
,
Y. R. Kim
,
K. Eikermann-Haerter
,
Philip K. Liu
The FASEB Journal
2008
Corpus ID: 26276199
We aimed to test the feasibility of detecting gliosis in living brains when the blood‐brain barrier (BBB) is disrupted. We…
Expand
2005
2005
Systemic and Periocular Deliveries of Plasminogen Kringle 5 Reduce Vascular Leakage in Rat Models of Oxygen-Induced Retinopathy and Diabetes
Sarah X. Zhang
,
J. Sima
,
J. Wang
,
C. Shao
,
J. Fant
,
Jian-xing Ma
Current Eye Research
2005
Corpus ID: 949967
Purpose: Increased retinal vascular permeability is a common complication of diabetes and a major cause of vision loss in…
Expand
2002
2002
Cyclosporin-A-2%-Augentropfen in der Therapie der Keratoconjunctivitis atopica und vernalis
I. Tomida
,
T. Schlote
,
J. Bräuning
,
P. Heide
,
M. Zierhut
Der Ophthalmologe
2002
Corpus ID: 45671047
ZusammenfassungHintergrund. Die Wirkung von Cyclosporin-A-2%-AT (CsA2%-AT) zur Behandlung der atopischen (AKC) und vernalen…
Expand
2000
2000
[Toxicity of preserved and unpreserved beta-blocker eyedrops in an in vitro model of human conjunctival cells].
M. De Saint Jean
,
C. Debbasch
,
F. Brignole
,
P. Rat
,
J. Warnet
,
C. Baudouin
Journal Francais d'Ophtalmologie
2000
Corpus ID: 24375180
PURPOSE To compare the toxicity of a short-time application of timolol with benzalkonium chloride (timolol-BAC+) and unpreserved…
Expand
1997
1997
Verbesserung der Augentropfenapplikation und Compliance bei Glaukompatienten - Eine klinische Studie
S. Busche
,
E. Gramer
1997
Corpus ID: 58375399
Hintergrund Patienten und Methode Ergebnisse Schlußfolgerung Background Patients and methods Results Conclusion
1997
1997
Corneal Epithelial Deficiency Induced by the Use of β-Blocker Eye Drops
Y. Haruta
,
Y. Ohashi
,
S. Matsuda
1997
Corpus ID: 77289958
Two studies were conducted to check the effects of β-blocker eye drops, 2% carteolol (Mikelan®) and 0.5% timolol (Timoptol®), on…
Expand
1993
1993
Comparative efficacy of the B-1 and VG/GA vaccine strains against velogenic viscerotropic Newcastle disease virus in chickens.
C. Beard
,
P. Villegas
,
J. Glisson
Avian diseases
1993
Corpus ID: 33391595
Groups of eight 1-day-old white rock chickens were vaccinated with either B-1 or VG/GA strain of Newcastle disease virus (NDV) by…
Expand
1989
1989
Studies of infectious laryngotracheitis vaccines: immunity in broilers.
J. R. Andreasen
,
J. Glisson
,
M. Goodwin
,
R. Resurreccion
,
P. Villegas
,
J. Brown
Avian diseases
1989
Corpus ID: 11634774
Broiler chickens were vaccinated at 18 days of age against infectious laryngotracheitis (ILT) using chicken-embryo-origin (CEO…
Expand
1987
1987
Timolol/pilocarpine combination eye drops in open angle glaucoma and in ocular hypertension
G. Høvding
,
H. Aasved
Acta ophthalmologica
1987
Corpus ID: 38331175
Abstract The effect of a newly developed ophthalmic solution containing both 0.5% timolol and 2% resp. 4% pilocarpine was…
Expand
1979
1979
The combination of guanethidine 3% and adrenaline 0.5% in 1 eyedrop (GA) in glaucoma treatment.
P. Hoyng
,
And
,
C. Dake
British Journal of Ophthalmology
1979
Corpus ID: 22789326
During a 7-month period 33 patients (20 with primary open-angle glaucoma and 13 with suspected glaucoma) were treated with…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE